JP2007509106A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509106A5
JP2007509106A5 JP2006536068A JP2006536068A JP2007509106A5 JP 2007509106 A5 JP2007509106 A5 JP 2007509106A5 JP 2006536068 A JP2006536068 A JP 2006536068A JP 2006536068 A JP2006536068 A JP 2006536068A JP 2007509106 A5 JP2007509106 A5 JP 2007509106A5
Authority
JP
Japan
Prior art keywords
methyl
amino
pyridinyl
pyrimidinyl
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006536068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509106A (ja
JP4827737B2 (ja
Filing date
Publication date
Priority claimed from GBGB0325031.3A external-priority patent/GB0325031D0/en
Application filed filed Critical
Publication of JP2007509106A publication Critical patent/JP2007509106A/ja
Publication of JP2007509106A5 publication Critical patent/JP2007509106A5/ja
Application granted granted Critical
Publication of JP4827737B2 publication Critical patent/JP4827737B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006536068A 2003-10-27 2004-10-26 アミロイド関連疾患の処置のためのピリジニル−ピリミジニルアミノ−ベンズアミド誘導体の使用 Expired - Fee Related JP4827737B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0325031.3A GB0325031D0 (en) 2003-10-27 2003-10-27 Organic compounds
GB0325031.3 2003-10-27
PCT/EP2004/012080 WO2005039586A1 (en) 2003-10-27 2004-10-26 Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders

Publications (3)

Publication Number Publication Date
JP2007509106A JP2007509106A (ja) 2007-04-12
JP2007509106A5 true JP2007509106A5 (https=) 2007-12-13
JP4827737B2 JP4827737B2 (ja) 2011-11-30

Family

ID=29725439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536068A Expired - Fee Related JP4827737B2 (ja) 2003-10-27 2004-10-26 アミロイド関連疾患の処置のためのピリジニル−ピリミジニルアミノ−ベンズアミド誘導体の使用

Country Status (4)

Country Link
US (1) US7687512B2 (https=)
JP (1) JP4827737B2 (https=)
GB (1) GB0325031D0 (https=)
WO (1) WO2005039586A1 (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070107022A (ko) 2005-01-07 2007-11-06 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
ES2373912T3 (es) * 2005-01-28 2012-02-10 Novartis Ag Uso de pirimidilaminobenzamidas para el tratamiento de enfermedades que responden a la modulación de la actividad de quinasa tie-2.
MX2007013738A (es) * 2005-05-02 2008-01-24 Novartis Ag Derivados de pirimidilaminobenzamida para sindrome hipereosinofilico.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
ES2549327T3 (es) 2005-12-06 2015-10-27 Novartis Ag Derivados de pirimidilaminobenzamida para el tratamiento de la neurofibromatosis
WO2007076875A2 (en) * 2006-01-06 2007-07-12 Aarhus Universitet Compounds acting on the serotonin transporter
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
MX2009004314A (es) 2006-11-13 2009-05-05 Pfizer Prod Inc Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos.
ME02372B (me) 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
US8242271B2 (en) 2007-06-04 2012-08-14 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
ES2607794T3 (es) * 2007-06-07 2017-04-04 Intra-Cellular Therapies, Inc. Compuestos heterocíclicos novedosos y usos de los mismos
WO2008153959A1 (en) * 2007-06-07 2008-12-18 Intra-Cellular Therapies, Inc. Novel heterocycle compounds and uses thereof
WO2009036066A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
WO2009143211A2 (en) 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
BRPI0917491A2 (pt) * 2008-08-13 2015-12-01 Novartis Ag tratamento de hipertensao arterial pulmonar
US20110243957A1 (en) * 2008-09-24 2011-10-06 University Of South Florida Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation
EP2340244A4 (en) * 2008-10-14 2012-07-25 Ning Xi COMPOUNDS AND APPLICATION PROCEDURES
EP2262793B1 (en) 2008-11-05 2012-10-03 Teva Pharmaceutical Industries Ltd. Nilotinib hci crystalline forms
WO2010060074A1 (en) * 2008-11-24 2010-05-27 Teva Pharmaceutical Industries Ltd. Preparation of nilotinib and intermediates thereof
CN102316738A (zh) * 2009-02-18 2012-01-11 盛泰萨路申有限公司 作为激酶抑制剂的酰胺类
ES2578990T3 (es) * 2009-03-21 2016-08-03 Sunshine Lake Pharma Co., Ltd. Derivados de amino éster, sales de los mismos y métodos de uso
SG178279A1 (en) 2009-08-05 2012-03-29 Intra Cellular Therapies Inc Novel regulatory proteins and inhibitors
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
EP2554163A4 (en) * 2010-03-26 2013-07-17 Univ Hokkaido Nat Univ Corp THERAPEUTIC ACTIVE FOR NEURODEGENERATIVE DISEASES
EP2736904B1 (en) 2011-07-27 2016-03-16 AB Science Oxazole and thiazole derivatives as selective protein kinase inhibitors (c-kit)
WO2013166295A1 (en) 2012-05-02 2013-11-07 Georgetown University Treating neural disease with tyrosine kinase inhibitors
EP3080103B9 (en) * 2013-12-11 2018-09-19 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
EP3275440B1 (en) 2015-03-25 2022-05-04 National Center for Geriatrics and Gerontology Novel oxadiazole derivative and pharmaceutical containing same
CN105030776A (zh) * 2015-06-24 2015-11-11 北京键凯科技有限公司 Src蛋白抑制剂在制备预防和/治疗阿尔兹海默病药物中的应用
CN106905298A (zh) * 2015-12-22 2017-06-30 江苏先声药业有限公司 盐酸尼洛替尼杂质的制备方法
US11426406B2 (en) 2017-02-09 2022-08-30 Georgetown University Compositions and methods for treating lysosomal storage disorders
WO2018207154A1 (en) * 2017-05-12 2018-11-15 The Hong Kong University Of Science And Technology Heterocyclic compounds as epha4 inhibitors
WO2020056132A1 (en) * 2018-09-13 2020-03-19 University Of Southern California Novel fgfr inhibitors and uses thereof
JP7629200B2 (ja) 2018-11-20 2025-02-13 ジョージタウン ユニバーシティ 神経変性、筋変性及びリソソーム蓄積障害を治療するための組成物及び方法
CA3132730A1 (en) * 2019-03-05 2020-09-10 Hongyi & Associates Llc Compounds for treating neurodegenerative diseases and cancers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
KR100330553B1 (ko) 1993-10-01 2002-11-27 노파르티스 아게 약물학적활성피리딘유도체및그의제조방법
US7064215B2 (en) * 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
US7910586B2 (en) 2002-01-04 2011-03-22 The Rockefeller University Compositions and methods for prevention and treatment of amyloid-β peptide-related disorders
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2007509106A5 (https=)
JP4827737B2 (ja) アミロイド関連疾患の処置のためのピリジニル−ピリミジニルアミノ−ベンズアミド誘導体の使用
CN1960731B (zh) 调节炎性和转移过程的方法
AU2001248324B2 (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
WO2009017455A1 (en) A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
AU2016216636B2 (en) Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity
JP2011530607A5 (https=)
JP2009542638A5 (https=)
JP2007523181A5 (https=)
HUP0202399A2 (hu) Dopamin D3 receptor ligandumok alkalmazása veseelégtelenség kezelésére szolgáló gyógyszerek előállítására
JP2009532438A5 (https=)
RU2304436C2 (ru) Применение производных n-фенил-2-пиримидинамина против основывающихся на мастоцитах заболеваний, подобных аллергическим нарушениям
AU2020229558A1 (en) Combinational medication
WO2018216705A1 (ja) 神経変性疾患の予防及び／又は治療剤
RU2011105059A (ru) Применение производных пиримидиламинобензамида для лечения фиброза
TWI565466B (zh) 由α－碳酸酐酶之異形體調節之哺乳動物之疾病之治療
JP2009537606A5 (https=)
BRPI0710496A2 (pt) combinação que compreende a) composto de pirimidilaminobenzamida e b) inibidor de thr315iie cinase
RU2007132255A (ru) Применение пиримидиламинобензамидов для лечения заболеваний, чувствительных к модуляции активности киназы tie-2
JP5936821B2 (ja) チロシンキナーゼ型受容体ｋｉｔによって媒介される増殖性疾患のイマチニブによる処置を最適化する方法
AU2011202833B2 (en) Combination comprising a) a pyrimidylaminobenzamide compound, and b) a Thr315lle kinase inhibitor
CN116829548A (zh) 作为c-abl抑制剂的吡唑衍生物
CN101484172A (zh) 包含a)嘧啶基氨基苯甲酰胺化合物和b)thr315lle激酶抑制剂的组合
AU2005244525A1 (en) Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy